ACADIA Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Inc.
12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://www.acadia-pharm.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 540
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Stephen R. Davis J.D. | CEO & Director | 1.03M | N/D | 1961 |
| Dr. Srdjan R. Stankovic M.D., M.S.P.H. | Pres | 933.1k | 2.04M | 1957 |
| Mr. Mark C. Schneyer | Exec. VP & CFO | 555.49k | N/D | 1974 |
| Mr. Brendan P. Teehan | Exec. VP, COO & Head of Commercial | 486.47k | N/D | 1969 |
| Mr. Austin D. Kim | Exec. VP, Gen. Counsel & Sec. | 559.24k | N/D | 1964 |
| Mr. James K. Kihara | VP, Chief Accounting Officer & Corp. Controller | N/D | N/D | 1981 |
| Mr. Bob Mischler | Sr. VP of Strategy & Technology Operations | N/D | N/D | N/D |
| Mr. Mark C. Johnson | VP of Investor Relations | N/D | N/D | N/D |
| Ms. Julie Fisher | Sr. VP of Marketing & Commercial Strategy | N/D | N/D | N/D |
| Ms. Holly Valdiviez | Sr. VP & Head of Sales | N/D | N/D | N/D |
Descripción
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de ACADIA Pharmaceuticals Inc. a partir del 1 de octubre de 2022 es 6. Las puntuaciones principales son Auditoría: 7; Junta: 6; Derechos del accionista: 8; Compensación: 5.
